In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Falsified Medicines Directive: end of transition period and beginning of monitoring activities

Falsified Medicines Directive: end of transition period and beginning of monitoring activities

by In2Pharma | Nov 4, 2019 | News

Belgium From 9 February  2019, all prescription and reimbursable medicines on the market must bear safety features. At each link in the distribution chain, the safety features must be checked so that the authenticity of the medicine upon delivery can be guaranteed....

Recent Posts

  • Planned legislative updates NL
  • Update RD 06.09.2017 pregabalin/gabapentin
  • Update New Inspection Platform GDP – FAMHP
  • Luxembourg tightens rules on nicotine pouches and novel nicotine products from 2026  
  • Specific claims in NL for food supplements

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België